Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the develo...
Puma Biotechnology, Inc. is a biopharmaceutical...
CPSI is a leading provider of healthcare solutions and services for community hosp...
CPSI is a leading provider of healthcare soluti...
Chimerix is a development-stage biopharmaceutical company dedicated to acceleratin...
Chimerix is a development-stage biopharmaceutic...
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers...
At Biogen, our mission is clear: we are pioneer...
TransMedics is a commercial-stage medical technology company transforming organ tr...
TransMedics is a commercial-stage medical techn...
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerati...
BioCardia, Inc., headquartered in San Carlos, C...
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...
CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the develo...
Puma Biotechnology, Inc. is a biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.